Core Insights - Neuronetics, Inc. has appointed Dan Reavers as the new President and CEO, effective March 23, indicating a leadership transition aimed at driving future growth [1] - The company reported strong fourth-quarter results with a 23% adjusted pro forma revenue growth, attributed to the successful integration of Greenbrook and increased treatment volumes [5][17] - Positive operating cash flow was achieved in Q4, marking a significant milestone for the company [6] Financial Performance - Total revenue for Q4 2025 was $41.8 million, an 86% increase from $22.5 million in Q4 2024, primarily due to the inclusion of Greenbrook operations [17] - NeuroStar business revenue was $18.3 million, reflecting a 9% pro forma increase year-over-year [17] - Gross margin decreased to 52% from 66% in the prior year, largely due to the lower margin of Greenbrook's clinic business [19] Operational Highlights - Clinic revenue grew 28% on an adjusted pro forma basis, with a significant increase in the referring provider network, adding 430 new providers in Q4 [6][12] - The company executed over 47,000 physician outreach activities, resulting in a 46% increase in patient referrals [7] - The rollout of SPRAVATO is nearly complete, with 84 clinics now offering the treatment [7] Strategic Initiatives - Neuronetics is focused on expanding its NeuroStar TMS systems market access through new models tailored to customer needs [26][27] - The company aims to address the unmet need for treatment-resistant depression (TRD) patients, with plans to advance collaboration with COMPASS Pathways on COMP360 psilocybin [28][29] - The infrastructure built for SPRAVATO is expected to facilitate the launch of new therapies, enhancing patient access and treatment options [30][31] Future Guidance - For 2026, total revenue is projected to be between $160 million and $166 million, indicating over 9% growth compared to 2025 [22] - The company anticipates strong growth in its clinic business, with double-digit year-over-year increases, while the NeuroStar business is expected to grow in the low to mid-single digits [22] - Operating expenses are expected to be between $100 million and $105 million, with a focus on efficiency improvements [23]

Core Insights - Neuronetics reported strong growth in the fourth quarter of 2025, with total revenue reaching $41.8 million, an 86% increase year-over-year, primarily due to the inclusion of Greenbrook operations [12] - The company is focused on building a vertically integrated mental health company post-Greenbrook acquisition, combining technology and clinical infrastructure to enhance patient access to treatment [5][6] - Neuronetics is implementing various operational improvements and strategic initiatives to drive growth in its NeuroStar TMS systems and Greenbrook clinics [19][20] Financial Performance - Fourth-quarter total revenue was $41.8 million, up 86% year-over-year, with adjusted pro forma revenue increasing 23% [12] - NeuroStar revenue for the quarter was $18.3 million, representing 9% growth year-over-year, while U.S. system revenue was $4.4 million, up 15% [13] - Clinic revenue reached $23.5 million, reflecting 37% adjusted pro forma growth, driven by increased treatments across NeuroStar TMS and Spravato [14] Operational Developments - The rollout of Spravato is nearly complete, with 84 clinics providing the treatment, and total treatment volume across Spravato and TMS rose 18% year-over-year in Q4 [1] - Management is standardizing operations across the clinic network, including deploying tablet kiosks for streamlined check-in and piloting a patient portal for digital intake [6] - The BetterMe Provider program ended 2025 with over 420 active sites, connecting more than 66,000 patients with BMP providers [8] Leadership and Strategic Direction - Dan Reuvers has been appointed as the new president and CEO, effective March 23, 2026, succeeding Keith Sullivan [6][4] - The company is focused on expanding customer acquisition models for NeuroStar TMS systems and increasing demand for depression treatments at Greenbrook clinics [19] - Neuronetics is collaborating with Compass Pathways on COMP360 psilocybin for treatment-resistant depression, with plans for an NDA submission [20][21] Cash Flow and Future Outlook - Total cash at the end of 2025 was $34.1 million, with positive cash flow from operations of $0.9 million in Q4 [16] - For 2026, the company projects total revenue between $160 million and $166 million, with expected growth in the clinic business in the double digits [18] - Operating cash flow is expected to be negative $13 million to negative $17 million for the full year, with improvements anticipated in the second half [18]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily due to the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Gross margin decreased to 52% in Q4 2025 from 66% in the prior year, attributed to the lower margin of Greenbrook's clinic business [19] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - Positive operating cash flow of $0.9 million in Q4 2025, marking a significant improvement from negative cash flow in previous quarters [21] Business Line Data and Key Metrics Changes - Clinic revenue grew 28% on an adjusted pro forma basis for the full year, with Q4 clinic revenue at $23.5 million, a 37% increase [6][18] - NeuroStar system revenue was $4.4 million in Q4, a 15% increase year-over-year, with 49 systems shipped [18] - Treatment session revenue for NeuroStar was $12.4 million in Q4, with a pro forma increase of 6% compared to the prior year [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [8] - TRICARE West expanded coverage for TMS therapy to include adolescents aged 15 and older, effective across 26 states [12] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding NeuroStar TMS systems to market and addressing the unmet need for treatment-resistant depression [25][26] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [27][29] - The company is focused on operational efficiencies and reducing overall expenses while driving towards sustainable operating cash flow [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to continue improving cash flow and operational efficiency, with expectations for positive cash flow in the second half of 2026 [21][24] - The company anticipates strong revenue performance in its clinic business, with growth in the double digits to mid-teens, while NeuroStar business is expected to grow in the low to mid-single digits [22] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026 [5] - The company has made a one-time principal payment of $5 million to reduce outstanding debt obligations and interest expenses [21] Q&A Session Summary Question: Insights on CID investigation in Florida and Michigan - Management confirmed ongoing cooperation with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [35] Question: Differences in patient monitoring for COMP360 - The treatment effect of COMP360 appears durable after one or two administrations, similar to Spravato, and will require certified healthcare settings for administration [38] Question: Cash position and Q1 cash burn - The $5 million payment to Perceptive came from non-restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [41][42] Question: Guidance on clinic growth and Spravato contribution - Majority of growth in the clinic is expected to come from volume, with Spravato growth anticipated to be higher than TMS [46][47] Question: Integration of COMP360 into current infrastructure - The existing infrastructure for Spravato clinics provides advantages for administering COMP360, with experienced staff and back-office support already in place [64]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Gross margin was 52% in Q4 2025, down from 66% in the prior year, due to the inclusion of Greenbrook's lower-margin clinic business [19] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] Business Line Data and Key Metrics Changes - Total revenue from the NeuroStar business was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a 6% increase on a pro forma basis compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [8] - TRICARE West expanded coverage for TMS therapy to include adolescents aged 15 and older, effective across 26 states [12] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [25][26] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [27][29] - The company is focused on operational efficiencies and expects to reduce operating expenses while driving revenue growth [22][23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to achieve positive operating cash flow and improve cash conversion through operational efficiencies [20][21] - The company anticipates strong revenue performance in 2026, with guidance for total revenue between $160 million and $166 million, representing over 9% growth versus 2025 [21][22] - Management acknowledged seasonality impacts on revenue, particularly in Q1, and noted weather-related challenges affecting patient access [51][54] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026 [5] - The company achieved positive operating cash flow in Q4 2025, marking a significant milestone [6] Q&A Session Summary Question: Insights on CID investigation in Florida and Michigan - Management confirmed ongoing cooperation with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [35] Question: Differences in patient monitoring for COMP360 - The Chief Technology Officer explained that COMP360 would be administered under a REMS protocol similar to Spravato, with durable treatment effects after one or two doses [38] Question: Cash position after debt payment - Management clarified that the $5 million payment to Perceptive came from non-restricted cash, leaving a comfortable cash balance for operations [41][42] Question: Guidance on clinic growth and Spravato - Management indicated that the majority of growth in the clinic business would come from volume, with Spravato expected to represent a growing share of treatment volume [46][47] Question: Integration of COMP360 into existing infrastructure - Management stated that the existing infrastructure and staff at Greenbrook clinics are well-prepared to administer COMP360 treatments [65]

Financial Data and Key Metrics Changes - Total revenue in Q4 2025 was $41.8 million, an increase of 86% compared to $22.5 million in Q4 2024, primarily driven by the inclusion of Greenbrook operations following the acquisition [17] - Adjusted pro forma revenue growth for Q4 was 23% year-over-year [17] - Net loss for Q4 2025 was $7.2 million, or $0.10 per share, compared to a net loss of $12.7 million, or $0.34 per share in the prior year [20] - EBITDA for Q4 2025 was negative $4.3 million, an improvement from negative $11 million in the prior year [20] - Cash provided by operations in Q4 was positive $0.9 million, marking a significant improvement from negative cash flow earlier in the year [21] Business Line Data and Key Metrics Changes - NeuroStar business revenue, including system and treatment session revenue, was $18.3 million in Q4 2025, representing a 9% increase on a pro forma basis [17] - U.S. NeuroStar system revenue was $4.4 million, a 15% year-over-year increase, with 49 systems shipped in the quarter [18] - U.S. treatment session revenue was $12.4 million, with a pro forma increase of 6% compared to the prior year [18] - Clinic revenue for Q4 was $23.5 million, a 37% increase on an adjusted pro forma basis, driven by growth in treatments across both NeuroStar TMS and Spravato [18] Market Data and Key Metrics Changes - The referring provider network added 430 new providers in Q4, a 25% increase year-over-year, contributing to over 1,300 new referrers added across 2025 [7] - Total treatment volume increased by 18% year-over-year in Q4 [9] - The expansion of TRICARE West coverage for TMS therapy to include adolescents aged 15 and older is a significant development for military families [13] Company Strategy and Development Direction - The company aims to leverage its integrated model to drive growth through expanding how NeuroStar TMS systems are brought to market and addressing the unmet need for treatment-resistant depression (TRD) [26][28] - Collaboration with Compass Pathways on COMP360 psilocybin is seen as a potential transformational treatment for TRD, with plans for commercial launch upon FDA approval [28][29] - The company is focused on operational efficiency and expects to reduce operating expenses to less than $100 million by Q4 2026 [23] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to drive revenue growth and achieve sustainable operating cash flow, with expectations for positive cash flow in the second half of 2026 [25] - The company acknowledges seasonality impacts on revenue, particularly in Q1, and is adapting its strategies accordingly [55][56] - Management highlighted the importance of maintaining strong relationships with primary care physicians and enhancing patient access to treatments [26] Other Important Information - The company appointed Dan Reuvers as the new President and CEO, effective March 23, 2026, indicating a leadership transition [5] - The company has made significant progress in integrating Greenbrook's operations, achieving positive operating cash flow and strengthening its balance sheet [16] Q&A Session Summary Question: Can you provide details on the CID investigation in Florida and Michigan? - Management confirmed that they are cooperating with the U.S. Attorney's Office regarding documentation for billing practices prior to the Greenbrook acquisition [36] Question: What are the profitability and patient monitoring differences for COMP360? - The treatment effect of COMP360 appears durable after one or two doses, and it will be administered under a REMS protocol similar to Spravato [40][42] Question: How did the $5 million payment to Perceptive affect cash position? - The payment did not come from restricted cash, and the company remains comfortable with its cash position despite projected Q1 cash burn [43][44] Question: Can you elaborate on the growth guidance for the clinic and standalone businesses? - Majority of growth in the clinic business is expected to come from volume, with Spravato growth anticipated to be significant in Q1 due to buy-and-bill impacts [50] Question: What are the integration requirements for the Compass collaboration? - The existing infrastructure for Spravato clinics will facilitate the integration of COMP360 treatments, with minimal additional updates needed [68]

Core Insights - Neuronetics reported a total revenue of $41.8 million in Q4 2025, marking an 86% increase compared to Q4 2024, and a projected full-year revenue for 2026 between $160 million and $166 million [1][6][25] Q4 2025 Highlights - Greenbrook clinic revenue reached $23.5 million in Q4 2025, up 428% as reported and 37% on an adjusted pro forma basis compared to Q4 2024 [1][6] - U.S. NeuroStar Advanced Therapy System revenue was $4.4 million, with 49 systems shipped [6][8] - Operating cash flow improved, with cash provided by operations of $0.9 million in Q4 2025 [1][19] Full Year 2025 Highlights - Total revenue for the full year 2025 was $149.2 million, a 99% increase compared to 2024, driven primarily by the acquisition of Greenbrook [6][13] - Greenbrook clinic revenue for the full year was $87.0 million, up 1,857% as reported and 28% on an adjusted pro forma basis compared to 2024 [6][16] - U.S. NeuroStar Advanced Therapy System revenue for the year was $14.3 million, a decrease of 7% compared to 2024 [14][15] Recent Operational Highlights - Dan Reuvers was appointed as President and CEO effective March 23, 2026, bringing over 30 years of experience in scaling commercial healthcare businesses [1][21] - The company is advancing its collaboration with Compass Pathways on COMP360 psilocybin for treatment-resistant depression, with promising Phase 3 study results [22][23] - TRICARE West expanded coverage for TMS therapy to include adolescents aged 15 and older, enhancing access to mental health treatment [24] Business Outlook - For Q1 2026, total worldwide revenue is expected to be between $33.0 million and $35.0 million [25] - Full-year 2026 projections include a gross margin of 47% to 49% and operating expenses of $100 million to $105 million [25][26]

Core Insights - Compass Pathways Plc reported strong clinical progress with its lead drug candidate, COMP360 psilocybin, achieving its primary goal in a Phase 3 trial for treatment-resistant depression (TRD) [1][5] - The company posted a GAAP net loss of $0.41 per share for Q2 2025, slightly better than the consensus estimate of $0.43 per share, with no revenue generated as expected for a pre-commercial entity [1][6] - The financial position improved, with cash and cash equivalents increasing to $221.9 million, expected to support operations into 2027 [7] Financial Performance - Q2 2025 GAAP EPS was $(0.41), an improvement of 26.8% from $(0.56) in Q2 2024 [2] - Research and Development expenses were $30.3 million, up 4.1% from $29.1 million in Q2 2024 [2] - General and Administrative expenses decreased by 11.9% year-over-year to $12.6 million [2] Clinical Developments - COMP360 demonstrated a statistically significant reduction in symptom severity in the COMP005 Phase 3 trial for TRD after six weeks [5] - The independent Data Safety Monitoring Board reported no unexpected safety issues during the trial [5] - The company is also advancing COMP360 into post-traumatic stress disorder (PTSD) with late-stage clinical trial design being finalized [8] Strategic Focus - Compass Pathways aims to provide clear evidence of clinical benefit and safety for COMP360, with priorities on late-stage clinical trials and regulatory submissions [4] - The company is preparing for commercialization, contingent on positive trial results and effective patient treatment planning post-approval [4] Future Outlook - Management did not provide formal revenue or earnings guidance but reaffirmed a target for full-year 2025 net cash used in operating activities of $120 to $145 million [9] - Key upcoming data releases include 26-week durability and long-term safety data from ongoing trials, expected by late 2026 [10] - The company is monitoring regulatory discussions and competitive landscape developments in the psychedelic treatment space [10]